Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Receives NYS Approval for Cancer Test

NEW YORK (GenomeWeb) – The New York State Department of Health has approved Response Genetics to market and report results from its ResponseDX tests to residents of the state, the company said today. 

The New York approval follows a two-day inspection of Response Genetics' CLIA laboratory in September. 

The company offers ResponseDX Biomarker tests for various cancer types, including lung, breast, and colon cancer. The tests use different technologies such as sequencing, PCR, and fluorescence in situ hybridization. Response Genetics also offers the microarray-based ResponseDX: Tissue of Origin Test for identifying challenging tumors, such as metastatic, poorly differentiated, and undifferentiated cancer. 

Response Genetics acquired the test when it bought the assets of Pathwork Diagnostics in 2013. 

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.